Literature DB >> 6831349

A new approach to the management of epidermoid carcinoma of the anal canal.

J Papillon, M Mayer, J F Montbarbon, J P Gerard, J L Chassard, C Bailly.   

Abstract

Until recently most squamous cell carcinomas of the anal canal were treated by radical surgery. Radiation therapy was only considered for palliation in case of inoperable tumors. Important progress has been made in the knowledge of the natural history of the disease and in the field of radiotherapy. Anal canal squamous cell carcinoma should not be treated any longer by the same procedure as adenocarcinoma of the lower rectum, because both these diseases differ markedly. Multimodality therapy with radiotherapy as first approach has been considered. This series of 121 cases treated since 1971 and followed more than three years suggests that three protocols based on irradiation followed or not by surgery should be used according to the extent of the disease. Of the 72 patients with resectable tumor, the five-year survival rate was 65%. Three-quarters of the patients cured had normal anal function. The rate of death from cancer was 18%. The method requires an accurate assessment of the extent of the tumor and of its pelvic lymphatic spread. Great care must be taken in planning treatment in a close cooperation between radiotherapist and surgeon.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831349     DOI: 10.1002/1097-0142(19830515)51:10<1830::aid-cncr2820511013>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy.

Authors:  J M Doniec; B Schniewind; G Kovács; V Kahlke; M Loehnert; B Kremer
Journal:  Surg Endosc       Date:  2006-01-21       Impact factor: 4.584

2.  Management of anal epidermoid carcinoma--an evaluation of treatment results in two population-based series.

Authors:  S Goldman; B Glimelius; U Glas; G Lundell; L Påhlman; E Ståhle
Journal:  Int J Colorectal Dis       Date:  1989-12       Impact factor: 2.571

Review 3.  Changing nature of anal cancer.

Authors:  R W Talbot
Journal:  BMJ       Date:  1988-07-23

Review 4.  Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy.

Authors:  Guillaume Klausner; Eivind Blais; Raphaël Jumeau; Julian Biau; Mailys de Meric de Bellefon; Mahmut Ozsahin; Thomas Zilli; Raymond Miralbell; Juliette Thariat; Idriss Troussier
Journal:  Med Oncol       Date:  2018-08-20       Impact factor: 3.064

5.  Dynamic management of squamous cell cancer of the anal canal.

Authors:  N D Nigro; V K Vaitkevicius; B Considine
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

6.  Transverse pelvic floor division for the posterior approach to the rectum and anus.

Authors:  E Gemsenjäger
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

7.  Multidisciplinary management of cancer of the anus.

Authors:  N D Nigro
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

Review 8.  Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).

Authors:  Eleonor Rivin Del Campo; Oscar Matzinger; Karin Haustermans; Didier Peiffert; Robert Glynne-Jones; Kathryn A Winter; Andre A Konski; Jaffer A Ajani; Jean-François Bosset; Jean-Michel Hannoun-Levi; Marc Puyraveau; A Bapsi Chakravarthy; Helen Meadows; John Northover; Laurence Collette; Melissa Christiaens; Philippe Maingon
Journal:  Eur J Cancer       Date:  2019-09-28       Impact factor: 9.162

9.  Conservative treatment of anorectal tumors.

Authors:  J Kovarik; V H Svoboda; B Higgins
Journal:  Strahlenther Onkol       Date:  1998-08       Impact factor: 3.621

10.  Anal epidermoid carcinoma: a population-based clinico-pathological study of 164 patients.

Authors:  S Goldman; B Glimelius; L Påhlman; E Ståhle; E Wilander
Journal:  Int J Colorectal Dis       Date:  1988-06       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.